Premium
The association of body mass index and prostate‐specific antigen in a population‐based study
Author(s) -
Baillargeon Jacques,
Pollock Brad H.,
Kristal Alan R.,
Bradshaw Patrick,
Hernandez Javier,
Basler Joseph,
Higgins Betsy,
Lynch Steve,
Rozanski Thomas,
Troyer Dean,
Thompson Ian
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20856
Subject(s) - medicine , body mass index , prostate cancer , overweight , prostate specific antigen , oncology , prostate , population , obesity , prostate carcinoma , carcinoma , stage (stratigraphy) , gynecology , cancer , paleontology , environmental health , biology
BACKGROUND Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced‐stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate‐specific antigen (PSA) is widely used to screen for prostate carcinoma. METHODS The authors examined the association between BMI and PSA in a population‐based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute. RESULTS The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age. CONCLUSIONS Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma. Cancer 2005. Published 2005 by the American Cancer Society.